Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer

• Main Authors: Jennifer L. Schehr (Author), Nan Sethakorn (Author), Zachery D. Schultz (Author), Camila I. Hernandez (Author), Rory M. Bade (Author), Diego Eyzaguirre (Author), Anupama Singh (Author), David J. Niles (Author), Leslie Henderson (Author), Jay W. Warrick (Author), Scott M. Berry (Author), Kaitlin E. Sundling (Author), David J. Beebe (Author), Ticiana A. Leal (Author), Joshua M. Lang (Author)
• Format: Book
• Published: BMC, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other components including HLA I expression. HLA I downregulation...